Common carotid artery

CES 2021 Mission for the human race, Pulxion's early detection technology is here to save lives

Thursday, January 14, 2021 - 8:04am

Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the team's research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

CES 2021 Mission for the Human Race, Pulxion’s Early Detection Technology Is Here to Save Lives.

Thursday, January 14, 2021 - 4:58am

Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the teams research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

Global Carotid Stents Industry

Wednesday, October 21, 2020 - 12:15pm

Table 13: Carotid Stents Market in Europe: A Historic Market

Key Points: 
  • Table 13: Carotid Stents Market in Europe: A Historic Market
    Table 15: Carotid Stents Market in France: Estimates and
    Table 17: Carotid Stents Market in Germany: Recent Past,
    Table 21: United Kingdom Market for Carotid Stents: Annual
    Table 22: Carotid Stents Market in the United Kingdom: Historic
    Table 26: Carotid Stents Market in Russia: A Historic Review in
    Forecasts in US$ Thousand by Region/Country: 2020-2027
    Table 30: Carotid Stents Market in Asia-Pacific: Historic
    Table 32: Carotid Stents Market in Australia: Recent Past,
    Table 36: Carotid Stents Market in South Korea: Recent Past,
    Table 38: Rest of Asia-Pacific Market for Carotid Stents:
    Table 39: Carotid Stents Market in Rest of Asia-Pacific:
    Breakdown of Sales by Region/Country: 2012, 2020, and 2027
    Table 44: Carotid Stents Market in Argentina in US$ Thousand:
    Table 45: Carotid Stents Market in Brazil: Estimates and
    Table 47: Carotid Stents Market in Mexico: Recent Past, Current
    and Projections in US$ Thousand: 2020 to 2027
    Table 50: Carotid Stents Market in Rest of Latin America:
    Forecasts in US$ Thousand by Region/Country: 2020-2027
    Table 54: Iranian Market for Carotid Stents: Annual Sales
    Table 55: Carotid Stents Market in Iran: Historic Sales
    Table 57: Carotid Stents Market in Israel in US$ Thousand:
    Table 60: Carotid Stents Market in the United Arab Emirates:
    Table 62: Carotid Stents Market in Rest of Middle East: Recent
    Table 65: Carotid Stents Market in Africa: A Historic Review in

Compelling Outcomes with TCAR vs. CEA in Patients with Carotid Artery Stenosis Published in the Annals of Surgery

Monday, September 21, 2020 - 2:00pm

These promising outcomes will likely increase the role of TCAR in the management of carotid artery stenosis.

Key Points: 
  • These promising outcomes will likely increase the role of TCAR in the management of carotid artery stenosis.
  • The study evaluated patients who underwent carotid procedures between 2016 and 2019, with 6,384 patients in each group analyzed using propensity score matching.
  • Additionally, there were no statistical differences noted between TCAR and CEA for in-hospital stroke/death (TCAR, 1.6%; CEA, 1.6%, p=0.945) as well as stroke (TCAR, 1.4%; CEA, 1.4%, p=0.881) and death (TCAR, 0.4%; CEA, 0.3%, p=0.662).
  • The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR).

InspireMD Gains Registration Clearance of its CGuard™ Embolic Prevention System (EPS) in Brazil

Thursday, July 23, 2020 - 1:00pm

Regulatory approval of CGuard EPS in Brazil reflects not only the ANVISA'S recognition of CGuards differentiating features versus conventional carotid stents, but also the need for safer treatments for carotid artery disease.

Key Points: 
  • Regulatory approval of CGuard EPS in Brazil reflects not only the ANVISA'S recognition of CGuards differentiating features versus conventional carotid stents, but also the need for safer treatments for carotid artery disease.
  • Brazil ranks as the sixthlargest populated country in world and the largest healthcare market in Latin America.
  • With a population over 213 million, Brazil represents an important step toward expanding commercial availability of InspireMD products into new territories.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.

Results Demonstrating Favorable Outcomes with TCAR vs. TF-CAS in Patients with Carotid Artery Stenosis Published in the Journal of the American Medical Association (JAMA)

Tuesday, December 17, 2019 - 10:01pm

I am confident that the growing evidence base coupled with publication of these data in JAMA, a peer-reviewed journal, will incrementally drive TCAR towards standard of care.

Key Points: 
  • I am confident that the growing evidence base coupled with publication of these data in JAMA, a peer-reviewed journal, will incrementally drive TCAR towards standard of care.
  • The study evaluated patients who underwent carotid procedures between 2016 and 2019, with 5,251 patients receiving TCAR compared to 6,640 patients receiving TF-CAS, with 3,286 patients in each group analyzed using propensity score matching.
  • Additionally, there were no statistical differences noted between TCAR and TF-CAS for in-hospital myocardial infarction (TCAR, 0.2%; TF-CAS, 0.3%, p=0.47).
  • The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR).

Global Carotid Stents Industry

Tuesday, October 22, 2019 - 3:00pm

Table 15: Carotid Stents Market in Europe: A Historic Market

Key Points: 
  • Table 15: Carotid Stents Market in Europe: A Historic Market
    Table 17: Carotid Stents Market in Germany: Recent Past,
    Table 21: United Kingdom Market for Carotid Stents: Annual
    Table 22: Carotid Stents Market in the United Kingdom: Historic
    Table 26: Carotid Stents Market in Russia: A Historic Review in
    Forecasts in US$ Thousand by Region/Country: 2018-2025
    Table 30: Carotid Stents Market in Asia-Pacific: Historic
    Table 32: Carotid Stents Market in Australia: Recent Past,
    Table 36: Carotid Stents Market in South Korea: Recent Past,
    Table 38: Rest of Asia-Pacific Market for Carotid Stents:
    Table 39: Carotid Stents Market in Rest of Asia-Pacific:
    Table 41: Carotid Stents Market in Argentina in US$ Thousand: A
    Breakdown of Sales by Region/Country: 2009, 2019, and 2025
    Table 45: Carotid Stents Market in Brazil: Estimates and
    Table 47: Carotid Stents Market in Mexico: Recent Past, Current
    and Projections in US$ Thousand: 2018 to 2025
    Table 50: Carotid Stents Market in Rest of Latin America: A
    Forecasts in US$ Thousand by Region/Country: 2018-2025
    Table 54: Iranian Market for Carotid Stents: Annual Sales
    Table 55: Carotid Stents Market in Iran: Historic Sales
    Table 57: Carotid Stents Market in Israel in US$ Thousand: A
    Table 60: Carotid Stents Market in the United Arab Emirates:
    Table 62: Carotid Stents Market in Rest of Middle East: Recent
    Table 65: Carotid Stents Market in Africa: A Historic Review in

Global Carotid Artery Stenosis Therapeutics Market - Forecast and Analysis 2019-2023 - ResearchAndMarkets.com

Thursday, October 10, 2019 - 3:47pm

Global Carotid Artery Stenosis Therapeutics Market: About this market

Key Points: 
  • Global Carotid Artery Stenosis Therapeutics Market: About this market
    The carotid artery stenosis therapeutics market analysis considers sales from antithrombotics, antihyperlipidemic, and antihypertensives products.
  • Also, our global carotid artery stenosis therapeutics market report looks at factors such as the increasing risk factors for carotid artery stenosis, increasing geriatric population, and growing awareness about carotid artery stenosis.
  • Global Carotid Artery Stenosis Therapeutics Market: Overview
    The growing awareness about carotid artery stenosis is important for its prevention, as delay in the diagnosis of this disease can be life-threatening.
  • The demand for carotid artery stenosis therapeutics is increasing with the growing awareness about stroke management and carotid artery stenosis through multiple educational programs initiated by government organizations.

Global Carotid Artery Stenosis Therapeutics Market 2019-2023 | Growing Awareness about Carotid Artery Stenosis to Boost Growth | Technavio

Thursday, September 26, 2019 - 10:00am
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190926005360/en/
    Technavio has announced its latest market research report titled global carotid artery stenosis therapeutics market 2019-2023 (Graphic: Business Wire)
    The growing awareness about carotid artery stenosis is important for its prevention, as delay in the diagnosis of this disease can be life-threatening.
  • Such awareness campaigns are expected to contribute to the growth of the carotid artery stenosis therapeutics market during the forecast period.
  • Global Carotid Artery Stenosis Therapeutics Market: Increasing Demand for Curative Therapies
    The high prevalence of carotid artery stenosis therapeutics and the lack of approved therapies has led to a huge unmet need for safe and effective curative therapies.
  • Global Carotid Artery Stenosis Therapeutics Market: Segmentation Analysis
    This market research report segments the global carotid artery stenosis therapeutics market by product (antithrombotics, antihyperlipidemics, and antihypertensives) and by region (North America, Europe, Asia, and ROW).

InspireMD Provides Business Update

Monday, September 9, 2019 - 1:05pm

TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today provided a business update.

Key Points: 
  • TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today provided a business update.
  • InspireMD also announced today that the company has been granted two new U.S. patents (No.
  • The FDA has concurred with the clinical study design which provides specificity on the clinical data requirements to support the market approval of the device.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.